Adynxx, Inc.
Adynxx, Inc. ADYX Peers
See (ADYX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADYX | $0.00 | N/A | 600 | N/A | -$0.03 | N/A |
| NONOF | $80.30 | -0.87% | 356.4B | 22.30 | $3.60 | +2.08% |
| CSLLY | $77.53 | -2.03% | 150.2B | 28.50 | $2.72 | +1.71% |
| CMXHF | $148.65 | -1.78% | 72B | 27.28 | $5.45 | +1.86% |
| UCBJF | $196.79 | +2.55% | 37.4B | 31.54 | $6.24 | +0.80% |
| UCBJY | $94.06 | -0.57% | 36.3B | 30.15 | $3.12 | +0.84% |
| ARGNF | $586.55 | N/A | 35.8B | 35.72 | $16.42 | N/A |
| ODTC | $22,005.00 | +29.44% | 24.1B | -0.08 | -$268,995.00 | N/A |
| IVBXF | $10.13 | N/A | 16.7B | -1013.20 | -$0.01 | N/A |
| WXXWY | $6.85 | -3.37% | 14B | 31.14 | $0.22 | N/A |
Stock Comparison
ADYX vs NONOF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, NONOF has a market cap of 356.4B. Regarding current trading prices, ADYX is priced at $0.00, while NONOF trades at $80.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas NONOF's P/E ratio is 22.30. In terms of profitability, ADYX's ROE is +0.00%, compared to NONOF's ROE of +0.81%. Regarding short-term risk, ADYX is less volatile compared to NONOF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CSLLY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CSLLY has a market cap of 150.2B. Regarding current trading prices, ADYX is priced at $0.00, while CSLLY trades at $77.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CSLLY's P/E ratio is 28.50. In terms of profitability, ADYX's ROE is +0.00%, compared to CSLLY's ROE of +0.26%. Regarding short-term risk, ADYX is less volatile compared to CSLLY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CMXHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CMXHF has a market cap of 72B. Regarding current trading prices, ADYX is priced at $0.00, while CMXHF trades at $148.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CMXHF's P/E ratio is 27.28. In terms of profitability, ADYX's ROE is +0.00%, compared to CMXHF's ROE of +0.15%. Regarding short-term risk, ADYX is less volatile compared to CMXHF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs UCBJF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, UCBJF has a market cap of 37.4B. Regarding current trading prices, ADYX is priced at $0.00, while UCBJF trades at $196.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas UCBJF's P/E ratio is 31.54. In terms of profitability, ADYX's ROE is +0.00%, compared to UCBJF's ROE of +0.03%. Regarding short-term risk, ADYX and UCBJF have similar daily volatility (0.00).
ADYX vs UCBJY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, UCBJY has a market cap of 36.3B. Regarding current trading prices, ADYX is priced at $0.00, while UCBJY trades at $94.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas UCBJY's P/E ratio is 30.15. In terms of profitability, ADYX's ROE is +0.00%, compared to UCBJY's ROE of +0.03%. Regarding short-term risk, ADYX is less volatile compared to UCBJY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ARGNF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ARGNF has a market cap of 35.8B. Regarding current trading prices, ADYX is priced at $0.00, while ARGNF trades at $586.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ARGNF's P/E ratio is 35.72. In terms of profitability, ADYX's ROE is +0.00%, compared to ARGNF's ROE of +0.16%. Regarding short-term risk, ADYX is less volatile compared to ARGNF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ODTC Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ODTC has a market cap of 24.1B. Regarding current trading prices, ADYX is priced at $0.00, while ODTC trades at $22,005.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ODTC's P/E ratio is -0.08. In terms of profitability, ADYX's ROE is +0.00%, compared to ODTC's ROE of +0.07%. Regarding short-term risk, ADYX and ODTC have similar daily volatility (0.00).
ADYX vs IVBXF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, IVBXF has a market cap of 16.7B. Regarding current trading prices, ADYX is priced at $0.00, while IVBXF trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas IVBXF's P/E ratio is -1013.20. In terms of profitability, ADYX's ROE is +0.00%, compared to IVBXF's ROE of -0.01%. Regarding short-term risk, ADYX is less volatile compared to IVBXF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs WXXWY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, WXXWY has a market cap of 14B. Regarding current trading prices, ADYX is priced at $0.00, while WXXWY trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas WXXWY's P/E ratio is 31.14. In terms of profitability, ADYX's ROE is +0.00%, compared to WXXWY's ROE of +0.06%. Regarding short-term risk, ADYX is less volatile compared to WXXWY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs GNMSF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, GNMSF has a market cap of 13.8B. Regarding current trading prices, ADYX is priced at $0.00, while GNMSF trades at $224.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas GNMSF's P/E ratio is 13.16. In terms of profitability, ADYX's ROE is +0.00%, compared to GNMSF's ROE of +0.26%. Regarding short-term risk, ADYX is less volatile compared to GNMSF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs WXIBF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, WXIBF has a market cap of 13.1B. Regarding current trading prices, ADYX is priced at $0.00, while WXIBF trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas WXIBF's P/E ratio is 32.10. In terms of profitability, ADYX's ROE is +0.00%, compared to WXIBF's ROE of +0.06%. Regarding short-term risk, ADYX is less volatile compared to WXIBF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SBMFF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SBMFF has a market cap of 12.6B. Regarding current trading prices, ADYX is priced at $0.00, while SBMFF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SBMFF's P/E ratio is 35.23. In terms of profitability, ADYX's ROE is +0.00%, compared to SBMFF's ROE of +0.11%. Regarding short-term risk, ADYX and SBMFF have similar daily volatility (0.00).
ADYX vs SBHMY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SBHMY has a market cap of 8.5B. Regarding current trading prices, ADYX is priced at $0.00, while SBHMY trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SBHMY's P/E ratio is 32.69. In terms of profitability, ADYX's ROE is +0.00%, compared to SBHMY's ROE of +0.11%. Regarding short-term risk, ADYX is less volatile compared to SBHMY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs TRSBF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, TRSBF has a market cap of 7.2B. Regarding current trading prices, ADYX is priced at $0.00, while TRSBF trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas TRSBF's P/E ratio is 25.50. In terms of profitability, ADYX's ROE is +0.00%, compared to TRSBF's ROE of +0.11%. Regarding short-term risk, ADYX and TRSBF have similar daily volatility (0.00).
ADYX vs TLPPF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, TLPPF has a market cap of 5.4B. Regarding current trading prices, ADYX is priced at $0.00, while TLPPF trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas TLPPF's P/E ratio is 178.33. In terms of profitability, ADYX's ROE is +0.00%, compared to TLPPF's ROE of +0.14%. Regarding short-term risk, ADYX and TLPPF have similar daily volatility (0.00).
ADYX vs ABCZF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ABCZF has a market cap of 5.1B. Regarding current trading prices, ADYX is priced at $0.00, while ABCZF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ABCZF's P/E ratio is 2225.00. In terms of profitability, ADYX's ROE is +0.00%, compared to ABCZF's ROE of -0.01%. Regarding short-term risk, ADYX and ABCZF have similar daily volatility (0.00).
ADYX vs ZLDPF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ZLDPF has a market cap of 5B. Regarding current trading prices, ADYX is priced at $0.00, while ZLDPF trades at $70.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ZLDPF's P/E ratio is -26.45. In terms of profitability, ADYX's ROE is +0.00%, compared to ZLDPF's ROE of -0.13%. Regarding short-term risk, ADYX is less volatile compared to ZLDPF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs INCPF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, INCPF has a market cap of 4.9B. Regarding current trading prices, ADYX is priced at $0.00, while INCPF trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas INCPF's P/E ratio is -108.67. In terms of profitability, ADYX's ROE is +0.00%, compared to INCPF's ROE of -0.05%. Regarding short-term risk, ADYX and INCPF have similar daily volatility (0.00).
ADYX vs AKBLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, AKBLF has a market cap of 4.8B. Regarding current trading prices, ADYX is priced at $0.00, while AKBLF trades at $21.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas AKBLF's P/E ratio is 33.36. In terms of profitability, ADYX's ROE is +0.00%, compared to AKBLF's ROE of +0.18%. Regarding short-term risk, ADYX is less volatile compared to AKBLF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs GNNSF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, GNNSF has a market cap of 4.7B. Regarding current trading prices, ADYX is priced at $0.00, while GNNSF trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas GNNSF's P/E ratio is -27.50. In terms of profitability, ADYX's ROE is +0.00%, compared to GNNSF's ROE of -0.06%. Regarding short-term risk, ADYX and GNNSF have similar daily volatility (0.00).
ADYX vs LABFF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, ADYX is priced at $0.00, while LABFF trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas LABFF's P/E ratio is 28.95. In terms of profitability, ADYX's ROE is +0.00%, compared to LABFF's ROE of +0.39%. Regarding short-term risk, ADYX and LABFF have similar daily volatility (0.00).
ADYX vs CAMRF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CAMRF has a market cap of 3.9B. Regarding current trading prices, ADYX is priced at $0.00, while CAMRF trades at $67.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CAMRF's P/E ratio is 70.64. In terms of profitability, ADYX's ROE is +0.00%, compared to CAMRF's ROE of +0.14%. Regarding short-term risk, ADYX is less volatile compared to CAMRF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs REGMF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, REGMF has a market cap of 3.6B. Regarding current trading prices, ADYX is priced at $0.00, while REGMF trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas REGMF's P/E ratio is -13.32. In terms of profitability, ADYX's ROE is +0.00%, compared to REGMF's ROE of -0.48%. Regarding short-term risk, ADYX is less volatile compared to REGMF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SHJBF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SHJBF has a market cap of 3B. Regarding current trading prices, ADYX is priced at $0.00, while SHJBF trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SHJBF's P/E ratio is -10.94. In terms of profitability, ADYX's ROE is +0.00%, compared to SHJBF's ROE of -0.27%. Regarding short-term risk, ADYX is less volatile compared to SHJBF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs TKBIF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, TKBIF has a market cap of 2.8B. Regarding current trading prices, ADYX is priced at $0.00, while TKBIF trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas TKBIF's P/E ratio is 18.71. In terms of profitability, ADYX's ROE is +0.00%, compared to TKBIF's ROE of N/A. Regarding short-term risk, ADYX and TKBIF have similar daily volatility (0.00).
ADYX vs MPSYF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, MPSYF has a market cap of 2.8B. Regarding current trading prices, ADYX is priced at $0.00, while MPSYF trades at $73.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas MPSYF's P/E ratio is -12.13. In terms of profitability, ADYX's ROE is +0.00%, compared to MPSYF's ROE of +2.51%. Regarding short-term risk, ADYX is less volatile compared to MPSYF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ASPHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ASPHF has a market cap of 2.2B. Regarding current trading prices, ADYX is priced at $0.00, while ASPHF trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ASPHF's P/E ratio is -35.83. In terms of profitability, ADYX's ROE is +0.00%, compared to ASPHF's ROE of -0.70%. Regarding short-term risk, ADYX and ASPHF have similar daily volatility (0.00).
ADYX vs BVNRY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BVNRY has a market cap of 2.2B. Regarding current trading prices, ADYX is priced at $0.00, while BVNRY trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BVNRY's P/E ratio is 10.94. In terms of profitability, ADYX's ROE is +0.00%, compared to BVNRY's ROE of +0.12%. Regarding short-term risk, ADYX is less volatile compared to BVNRY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BVNKF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BVNKF has a market cap of 2.1B. Regarding current trading prices, ADYX is priced at $0.00, while BVNKF trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BVNKF's P/E ratio is 10.66. In terms of profitability, ADYX's ROE is +0.00%, compared to BVNKF's ROE of +0.12%. Regarding short-term risk, ADYX is less volatile compared to BVNKF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BTTAY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BTTAY has a market cap of 1.9B. Regarding current trading prices, ADYX is priced at $0.00, while BTTAY trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BTTAY's P/E ratio is -67.31. In terms of profitability, ADYX's ROE is +0.00%, compared to BTTAY's ROE of +0.05%. Regarding short-term risk, ADYX is less volatile compared to BTTAY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BRCTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BRCTF has a market cap of 1.9B. Regarding current trading prices, ADYX is priced at $0.00, while BRCTF trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BRCTF's P/E ratio is 19.72. In terms of profitability, ADYX's ROE is +0.00%, compared to BRCTF's ROE of -0.19%. Regarding short-term risk, ADYX is less volatile compared to BRCTF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs PHMMF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PHMMF has a market cap of 1.8B. Regarding current trading prices, ADYX is priced at $0.00, while PHMMF trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PHMMF's P/E ratio is 80.38. In terms of profitability, ADYX's ROE is +0.00%, compared to PHMMF's ROE of +0.10%. Regarding short-term risk, ADYX is less volatile compared to PHMMF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs GLPGF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, GLPGF has a market cap of 1.8B. Regarding current trading prices, ADYX is priced at $0.00, while GLPGF trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas GLPGF's P/E ratio is -8.84. In terms of profitability, ADYX's ROE is +0.00%, compared to GLPGF's ROE of -0.06%. Regarding short-term risk, ADYX is less volatile compared to GLPGF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs GENSF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, GENSF has a market cap of 1.7B. Regarding current trading prices, ADYX is priced at $0.00, while GENSF trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas GENSF's P/E ratio is -289.00. In terms of profitability, ADYX's ROE is +0.00%, compared to GENSF's ROE of +0.01%. Regarding short-term risk, ADYX and GENSF have similar daily volatility (0.00).
ADYX vs BIESF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BIESF has a market cap of 1.6B. Regarding current trading prices, ADYX is priced at $0.00, while BIESF trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BIESF's P/E ratio is -44.44. In terms of profitability, ADYX's ROE is +0.00%, compared to BIESF's ROE of +0.05%. Regarding short-term risk, ADYX and BIESF have similar daily volatility (0.00).
ADYX vs PPTDF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PPTDF has a market cap of 1.5B. Regarding current trading prices, ADYX is priced at $0.00, while PPTDF trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PPTDF's P/E ratio is 14.75. In terms of profitability, ADYX's ROE is +0.00%, compared to PPTDF's ROE of +0.26%. Regarding short-term risk, ADYX is less volatile compared to PPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ONTTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ONTTF has a market cap of 1.5B. Regarding current trading prices, ADYX is priced at $0.00, while ONTTF trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ONTTF's P/E ratio is -6.93. In terms of profitability, ADYX's ROE is +0.00%, compared to ONTTF's ROE of -0.27%. Regarding short-term risk, ADYX is less volatile compared to ONTTF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BRAXF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BRAXF has a market cap of 1.3B. Regarding current trading prices, ADYX is priced at $0.00, while BRAXF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BRAXF's P/E ratio is -0.03. In terms of profitability, ADYX's ROE is +0.00%, compared to BRAXF's ROE of -2.49%. Regarding short-term risk, ADYX is less volatile compared to BRAXF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CSBTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CSBTF has a market cap of 1.3B. Regarding current trading prices, ADYX is priced at $0.00, while CSBTF trades at $33.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CSBTF's P/E ratio is -237.29. In terms of profitability, ADYX's ROE is +0.00%, compared to CSBTF's ROE of -0.15%. Regarding short-term risk, ADYX is less volatile compared to CSBTF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs MEOBF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, MEOBF has a market cap of 1.2B. Regarding current trading prices, ADYX is priced at $0.00, while MEOBF trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas MEOBF's P/E ratio is -10.67. In terms of profitability, ADYX's ROE is +0.00%, compared to MEOBF's ROE of -0.15%. Regarding short-term risk, ADYX and MEOBF have similar daily volatility (0.00).
ADYX vs NURPF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, NURPF has a market cap of 1.1B. Regarding current trading prices, ADYX is priced at $0.00, while NURPF trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas NURPF's P/E ratio is 12.48. In terms of profitability, ADYX's ROE is +0.00%, compared to NURPF's ROE of +0.49%. Regarding short-term risk, ADYX is less volatile compared to NURPF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SNBIF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SNBIF has a market cap of 1B. Regarding current trading prices, ADYX is priced at $0.00, while SNBIF trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SNBIF's P/E ratio is -22.59. In terms of profitability, ADYX's ROE is +0.00%, compared to SNBIF's ROE of -0.92%. Regarding short-term risk, ADYX is less volatile compared to SNBIF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ASCLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ASCLF has a market cap of 904M. Regarding current trading prices, ADYX is priced at $0.00, while ASCLF trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ASCLF's P/E ratio is -23.31. In terms of profitability, ADYX's ROE is +0.00%, compared to ASCLF's ROE of -0.09%. Regarding short-term risk, ADYX is less volatile compared to ASCLF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs PHGUF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PHGUF has a market cap of 806.2M. Regarding current trading prices, ADYX is priced at $0.00, while PHGUF trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PHGUF's P/E ratio is -59.25. In terms of profitability, ADYX's ROE is +0.00%, compared to PHGUF's ROE of -0.06%. Regarding short-term risk, ADYX is less volatile compared to PHGUF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BPMUF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BPMUF has a market cap of 708.1M. Regarding current trading prices, ADYX is priced at $0.00, while BPMUF trades at $57.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BPMUF's P/E ratio is 8.09. In terms of profitability, ADYX's ROE is +0.00%, compared to BPMUF's ROE of -0.01%. Regarding short-term risk, ADYX is less volatile compared to BPMUF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CSPHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CSPHF has a market cap of 703M. Regarding current trading prices, ADYX is priced at $0.00, while CSPHF trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CSPHF's P/E ratio is -51.80. In terms of profitability, ADYX's ROE is +0.00%, compared to CSPHF's ROE of -0.14%. Regarding short-term risk, ADYX is less volatile compared to CSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SOLTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SOLTF has a market cap of 632.7M. Regarding current trading prices, ADYX is priced at $0.00, while SOLTF trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SOLTF's P/E ratio is -38.89. In terms of profitability, ADYX's ROE is +0.00%, compared to SOLTF's ROE of -0.07%. Regarding short-term risk, ADYX is less volatile compared to SOLTF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BXPHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BXPHF has a market cap of 588.3M. Regarding current trading prices, ADYX is priced at $0.00, while BXPHF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BXPHF's P/E ratio is -30.00. In terms of profitability, ADYX's ROE is +0.00%, compared to BXPHF's ROE of -0.18%. Regarding short-term risk, ADYX is less volatile compared to BXPHF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs INRLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, INRLF has a market cap of 527.2M. Regarding current trading prices, ADYX is priced at $0.00, while INRLF trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas INRLF's P/E ratio is -4.84. In terms of profitability, ADYX's ROE is +0.00%, compared to INRLF's ROE of -0.43%. Regarding short-term risk, ADYX is less volatile compared to INRLF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs IVEVF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, IVEVF has a market cap of 506.3M. Regarding current trading prices, ADYX is priced at $0.00, while IVEVF trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas IVEVF's P/E ratio is -1.05. In terms of profitability, ADYX's ROE is +0.00%, compared to IVEVF's ROE of +1.67%. Regarding short-term risk, ADYX and IVEVF have similar daily volatility (0.00).
ADYX vs CLTEF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CLTEF has a market cap of 504.7M. Regarding current trading prices, ADYX is priced at $0.00, while CLTEF trades at $7.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CLTEF's P/E ratio is -7.06. In terms of profitability, ADYX's ROE is +0.00%, compared to CLTEF's ROE of -0.43%. Regarding short-term risk, ADYX and CLTEF have similar daily volatility (0.00).
ADYX vs VBIZF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, VBIZF has a market cap of 503.4M. Regarding current trading prices, ADYX is priced at $0.00, while VBIZF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas VBIZF's P/E ratio is 24.20. In terms of profitability, ADYX's ROE is +0.00%, compared to VBIZF's ROE of -0.00%. Regarding short-term risk, ADYX is less volatile compared to VBIZF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CKDXF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CKDXF has a market cap of 481.3M. Regarding current trading prices, ADYX is priced at $0.00, while CKDXF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CKDXF's P/E ratio is -1.26. In terms of profitability, ADYX's ROE is +0.00%, compared to CKDXF's ROE of +2.04%. Regarding short-term risk, ADYX is less volatile compared to CKDXF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs AAVXF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, AAVXF has a market cap of 461.8M. Regarding current trading prices, ADYX is priced at $0.00, while AAVXF trades at $7.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas AAVXF's P/E ratio is -2.16. In terms of profitability, ADYX's ROE is +0.00%, compared to AAVXF's ROE of -2.11%. Regarding short-term risk, ADYX is less volatile compared to AAVXF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CYDY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CYDY has a market cap of 436.3M. Regarding current trading prices, ADYX is priced at $0.00, while CYDY trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CYDY's P/E ratio is -17.70. In terms of profitability, ADYX's ROE is +0.00%, compared to CYDY's ROE of +0.07%. Regarding short-term risk, ADYX is less volatile compared to CYDY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs TBGNF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, TBGNF has a market cap of 433.7M. Regarding current trading prices, ADYX is priced at $0.00, while TBGNF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas TBGNF's P/E ratio is -0.25. In terms of profitability, ADYX's ROE is +0.00%, compared to TBGNF's ROE of N/A. Regarding short-term risk, ADYX and TBGNF have similar daily volatility (0.00).
ADYX vs IDRSF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, IDRSF has a market cap of 418.1M. Regarding current trading prices, ADYX is priced at $0.00, while IDRSF trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas IDRSF's P/E ratio is -1.13. In terms of profitability, ADYX's ROE is +0.00%, compared to IDRSF's ROE of +0.24%. Regarding short-term risk, ADYX is less volatile compared to IDRSF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs HBMHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, HBMHF has a market cap of 408M. Regarding current trading prices, ADYX is priced at $0.00, while HBMHF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas HBMHF's P/E ratio is 16.07. In terms of profitability, ADYX's ROE is +0.00%, compared to HBMHF's ROE of +0.02%. Regarding short-term risk, ADYX and HBMHF have similar daily volatility (0.00).
ADYX vs PTCHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PTCHF has a market cap of 403.5M. Regarding current trading prices, ADYX is priced at $0.00, while PTCHF trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PTCHF's P/E ratio is 8.00. In terms of profitability, ADYX's ROE is +0.00%, compared to PTCHF's ROE of -0.22%. Regarding short-term risk, ADYX is less volatile compared to PTCHF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs NWBO Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, NWBO has a market cap of 397.9M. Regarding current trading prices, ADYX is priced at $0.00, while NWBO trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas NWBO's P/E ratio is -4.60. In terms of profitability, ADYX's ROE is +0.00%, compared to NWBO's ROE of +1.13%. Regarding short-term risk, ADYX is less volatile compared to NWBO. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CLVLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CLVLF has a market cap of 361.9M. Regarding current trading prices, ADYX is priced at $0.00, while CLVLF trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CLVLF's P/E ratio is 14.44. In terms of profitability, ADYX's ROE is +0.00%, compared to CLVLF's ROE of +0.19%. Regarding short-term risk, ADYX and CLVLF have similar daily volatility (0.00).
ADYX vs CLVLY Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CLVLY has a market cap of 348.9M. Regarding current trading prices, ADYX is priced at $0.00, while CLVLY trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CLVLY's P/E ratio is 13.92. In terms of profitability, ADYX's ROE is +0.00%, compared to CLVLY's ROE of +0.19%. Regarding short-term risk, ADYX is less volatile compared to CLVLY. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs HLOSF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, HLOSF has a market cap of 321.6M. Regarding current trading prices, ADYX is priced at $0.00, while HLOSF trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas HLOSF's P/E ratio is -10.23. In terms of profitability, ADYX's ROE is +0.00%, compared to HLOSF's ROE of -1.30%. Regarding short-term risk, ADYX and HLOSF have similar daily volatility (0.00).
ADYX vs PBBIF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PBBIF has a market cap of 286.9M. Regarding current trading prices, ADYX is priced at $0.00, while PBBIF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PBBIF's P/E ratio is 266.67. In terms of profitability, ADYX's ROE is +0.00%, compared to PBBIF's ROE of +0.01%. Regarding short-term risk, ADYX is less volatile compared to PBBIF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs PRRUF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PRRUF has a market cap of 277.5M. Regarding current trading prices, ADYX is priced at $0.00, while PRRUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PRRUF's P/E ratio is -9.50. In terms of profitability, ADYX's ROE is +0.00%, compared to PRRUF's ROE of -0.28%. Regarding short-term risk, ADYX is less volatile compared to PRRUF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ORYZF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ORYZF has a market cap of 249.8M. Regarding current trading prices, ADYX is priced at $0.00, while ORYZF trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ORYZF's P/E ratio is -46.05. In terms of profitability, ADYX's ROE is +0.00%, compared to ORYZF's ROE of -0.05%. Regarding short-term risk, ADYX is less volatile compared to ORYZF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs NWPHF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, NWPHF has a market cap of 231.2M. Regarding current trading prices, ADYX is priced at $0.00, while NWPHF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas NWPHF's P/E ratio is N/A. In terms of profitability, ADYX's ROE is +0.00%, compared to NWPHF's ROE of N/A. Regarding short-term risk, ADYX and NWPHF have similar daily volatility (0.00).
ADYX vs MDCLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, MDCLF has a market cap of 230.7M. Regarding current trading prices, ADYX is priced at $0.00, while MDCLF trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas MDCLF's P/E ratio is -5.21. In terms of profitability, ADYX's ROE is +0.00%, compared to MDCLF's ROE of +0.60%. Regarding short-term risk, ADYX is less volatile compared to MDCLF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BSEM Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BSEM has a market cap of 224.8M. Regarding current trading prices, ADYX is priced at $0.00, while BSEM trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BSEM's P/E ratio is -24.14. In terms of profitability, ADYX's ROE is +0.00%, compared to BSEM's ROE of +1.50%. Regarding short-term risk, ADYX is less volatile compared to BSEM. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BOVNF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BOVNF has a market cap of 216.4M. Regarding current trading prices, ADYX is priced at $0.00, while BOVNF trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BOVNF's P/E ratio is -5.98. In terms of profitability, ADYX's ROE is +0.00%, compared to BOVNF's ROE of -0.50%. Regarding short-term risk, ADYX is less volatile compared to BOVNF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SLNCF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SLNCF has a market cap of 212.5M. Regarding current trading prices, ADYX is priced at $0.00, while SLNCF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SLNCF's P/E ratio is -2.94. In terms of profitability, ADYX's ROE is +0.00%, compared to SLNCF's ROE of -0.87%. Regarding short-term risk, ADYX and SLNCF have similar daily volatility (0.00).
ADYX vs RAONF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, RAONF has a market cap of 212M. Regarding current trading prices, ADYX is priced at $0.00, while RAONF trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas RAONF's P/E ratio is -20.33. In terms of profitability, ADYX's ROE is +0.00%, compared to RAONF's ROE of -0.71%. Regarding short-term risk, ADYX is less volatile compared to RAONF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs FPHAF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, FPHAF has a market cap of 209.5M. Regarding current trading prices, ADYX is priced at $0.00, while FPHAF trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas FPHAF's P/E ratio is -7.50. In terms of profitability, ADYX's ROE is +0.00%, compared to FPHAF's ROE of N/A. Regarding short-term risk, ADYX and FPHAF have similar daily volatility (0.00).
ADYX vs VSBC Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, VSBC has a market cap of 207M. Regarding current trading prices, ADYX is priced at $0.00, while VSBC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas VSBC's P/E ratio is N/A. In terms of profitability, ADYX's ROE is +0.00%, compared to VSBC's ROE of +0.00%. Regarding short-term risk, ADYX and VSBC have similar daily volatility (0.00).
ADYX vs FGHQF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, FGHQF has a market cap of 205.6M. Regarding current trading prices, ADYX is priced at $0.00, while FGHQF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas FGHQF's P/E ratio is 10.10. In terms of profitability, ADYX's ROE is +0.00%, compared to FGHQF's ROE of +0.00%. Regarding short-term risk, ADYX is less volatile compared to FGHQF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs HNSBF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, HNSBF has a market cap of 203.4M. Regarding current trading prices, ADYX is priced at $0.00, while HNSBF trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas HNSBF's P/E ratio is -2.34. In terms of profitability, ADYX's ROE is +0.00%, compared to HNSBF's ROE of +1.43%. Regarding short-term risk, ADYX is less volatile compared to HNSBF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs NGENF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, NGENF has a market cap of 198.6M. Regarding current trading prices, ADYX is priced at $0.00, while NGENF trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas NGENF's P/E ratio is -9.45. In terms of profitability, ADYX's ROE is +0.00%, compared to NGENF's ROE of -2.23%. Regarding short-term risk, ADYX is less volatile compared to NGENF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs GNFTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, GNFTF has a market cap of 176.3M. Regarding current trading prices, ADYX is priced at $0.00, while GNFTF trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas GNFTF's P/E ratio is 8.85. In terms of profitability, ADYX's ROE is +0.00%, compared to GNFTF's ROE of +0.27%. Regarding short-term risk, ADYX is less volatile compared to GNFTF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SCNLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SCNLF has a market cap of 176M. Regarding current trading prices, ADYX is priced at $0.00, while SCNLF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SCNLF's P/E ratio is -5.66. In terms of profitability, ADYX's ROE is +0.00%, compared to SCNLF's ROE of +2.45%. Regarding short-term risk, ADYX and SCNLF have similar daily volatility (0.00).
ADYX vs OPORF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, OPORF has a market cap of 164.9M. Regarding current trading prices, ADYX is priced at $0.00, while OPORF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas OPORF's P/E ratio is 12.00. In terms of profitability, ADYX's ROE is +0.00%, compared to OPORF's ROE of +0.42%. Regarding short-term risk, ADYX is less volatile compared to OPORF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs IPHYF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, IPHYF has a market cap of 159.9M. Regarding current trading prices, ADYX is priced at $0.00, while IPHYF trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas IPHYF's P/E ratio is -2.48. In terms of profitability, ADYX's ROE is +0.00%, compared to IPHYF's ROE of -1.81%. Regarding short-term risk, ADYX and IPHYF have similar daily volatility (0.00).
ADYX vs RECEF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, RECEF has a market cap of 157.2M. Regarding current trading prices, ADYX is priced at $0.00, while RECEF trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas RECEF's P/E ratio is -10.00. In terms of profitability, ADYX's ROE is +0.00%, compared to RECEF's ROE of +2.26%. Regarding short-term risk, ADYX is less volatile compared to RECEF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs MLLCF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, MLLCF has a market cap of 155.6M. Regarding current trading prices, ADYX is priced at $0.00, while MLLCF trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas MLLCF's P/E ratio is -2.04. In terms of profitability, ADYX's ROE is +0.00%, compared to MLLCF's ROE of -0.36%. Regarding short-term risk, ADYX is less volatile compared to MLLCF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs AVCTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, AVCTF has a market cap of 155.1M. Regarding current trading prices, ADYX is priced at $0.00, while AVCTF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas AVCTF's P/E ratio is -3.34. In terms of profitability, ADYX's ROE is +0.00%, compared to AVCTF's ROE of -1.24%. Regarding short-term risk, ADYX is less volatile compared to AVCTF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs SPHDF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, SPHDF has a market cap of 142.7M. Regarding current trading prices, ADYX is priced at $0.00, while SPHDF trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas SPHDF's P/E ratio is -3.27. In terms of profitability, ADYX's ROE is +0.00%, compared to SPHDF's ROE of +0.89%. Regarding short-term risk, ADYX is less volatile compared to SPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs BRIBF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, BRIBF has a market cap of 134.1M. Regarding current trading prices, ADYX is priced at $0.00, while BRIBF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas BRIBF's P/E ratio is -1.83. In terms of profitability, ADYX's ROE is +0.00%, compared to BRIBF's ROE of -0.10%. Regarding short-term risk, ADYX and BRIBF have similar daily volatility (0.00).
ADYX vs AAPGV Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, AAPGV has a market cap of 127.3M. Regarding current trading prices, ADYX is priced at $0.00, while AAPGV trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas AAPGV's P/E ratio is N/A. In terms of profitability, ADYX's ROE is +0.00%, compared to AAPGV's ROE of N/A. Regarding short-term risk, ADYX is less volatile compared to AAPGV. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs PRNAF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PRNAF has a market cap of 126.9M. Regarding current trading prices, ADYX is priced at $0.00, while PRNAF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PRNAF's P/E ratio is -1.39. In terms of profitability, ADYX's ROE is +0.00%, compared to PRNAF's ROE of -1.77%. Regarding short-term risk, ADYX and PRNAF have similar daily volatility (0.00).
ADYX vs AMGXF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, AMGXF has a market cap of 126.7M. Regarding current trading prices, ADYX is priced at $0.00, while AMGXF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas AMGXF's P/E ratio is -0.46. In terms of profitability, ADYX's ROE is +0.00%, compared to AMGXF's ROE of -0.24%. Regarding short-term risk, ADYX is less volatile compared to AMGXF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs PSTTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PSTTF has a market cap of 117.5M. Regarding current trading prices, ADYX is priced at $0.00, while PSTTF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PSTTF's P/E ratio is -29.00. In terms of profitability, ADYX's ROE is +0.00%, compared to PSTTF's ROE of N/A. Regarding short-term risk, ADYX and PSTTF have similar daily volatility (0.00).
ADYX vs EPRXF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, EPRXF has a market cap of 108.3M. Regarding current trading prices, ADYX is priced at $0.00, while EPRXF trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas EPRXF's P/E ratio is -2.69. In terms of profitability, ADYX's ROE is +0.00%, compared to EPRXF's ROE of -0.85%. Regarding short-term risk, ADYX is less volatile compared to EPRXF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ADOIF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ADOIF has a market cap of 103.7M. Regarding current trading prices, ADYX is priced at $0.00, while ADOIF trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ADOIF's P/E ratio is -2.59. In terms of profitability, ADYX's ROE is +0.00%, compared to ADOIF's ROE of +6.08%. Regarding short-term risk, ADYX and ADOIF have similar daily volatility (0.00).
ADYX vs JWCTF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, JWCTF has a market cap of 101.3M. Regarding current trading prices, ADYX is priced at $0.00, while JWCTF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas JWCTF's P/E ratio is -1.25. In terms of profitability, ADYX's ROE is +0.00%, compared to JWCTF's ROE of -0.47%. Regarding short-term risk, ADYX and JWCTF have similar daily volatility (0.00).
ADYX vs PBIGF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PBIGF has a market cap of 100M. Regarding current trading prices, ADYX is priced at $0.00, while PBIGF trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PBIGF's P/E ratio is -8.56. In terms of profitability, ADYX's ROE is +0.00%, compared to PBIGF's ROE of -2.16%. Regarding short-term risk, ADYX is less volatile compared to PBIGF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs PPCB Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, PPCB has a market cap of 92.8M. Regarding current trading prices, ADYX is priced at $0.00, while PPCB trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas PPCB's P/E ratio is -0.02. In terms of profitability, ADYX's ROE is +0.00%, compared to PPCB's ROE of -36.52%. Regarding short-term risk, ADYX and PPCB have similar daily volatility (0.00).
ADYX vs TRGNF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, TRGNF has a market cap of 92.4M. Regarding current trading prices, ADYX is priced at $0.00, while TRGNF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas TRGNF's P/E ratio is -2.12. In terms of profitability, ADYX's ROE is +0.00%, compared to TRGNF's ROE of -3.14%. Regarding short-term risk, ADYX is less volatile compared to TRGNF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs CMVLF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, CMVLF has a market cap of 90.1M. Regarding current trading prices, ADYX is priced at $0.00, while CMVLF trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas CMVLF's P/E ratio is -1.87. In terms of profitability, ADYX's ROE is +0.00%, compared to CMVLF's ROE of -0.30%. Regarding short-term risk, ADYX is less volatile compared to CMVLF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs ACHFF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, ACHFF has a market cap of 89M. Regarding current trading prices, ADYX is priced at $0.00, while ACHFF trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas ACHFF's P/E ratio is -33.75. In terms of profitability, ADYX's ROE is +0.00%, compared to ACHFF's ROE of +0.56%. Regarding short-term risk, ADYX is less volatile compared to ACHFF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.
ADYX vs MCURF Comparison
ADYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADYX stands at 600. In comparison, MCURF has a market cap of 86.5M. Regarding current trading prices, ADYX is priced at $0.00, while MCURF trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADYX currently has a P/E ratio of N/A, whereas MCURF's P/E ratio is -16.90. In terms of profitability, ADYX's ROE is +0.00%, compared to MCURF's ROE of -1.02%. Regarding short-term risk, ADYX is less volatile compared to MCURF. This indicates potentially lower risk in terms of short-term price fluctuations for ADYX.